Eton Pharmaceuticals has gained 108% over six months, driven by 99% Q2 product sales growth and successful Hemangeol relaunch. The company raised 2026 revenue guidance to above $145 million with 35%+ adjusted EBITDA margins. Pipeline expansion including new launches and late-stage candidates like ASN-001 provide additional growth opportunities.
ETON
Eton Pharmaceutcials, Inc. · NASDAQ
Sign up free to see this.
Mkt Cap
$1.4B
Volume
246.6K
52W High
$66.37
52W Low
$14.27
PE Ratio
112.6
Avg Vol
556.2K
As of 10/23/26
Div Yield
—
Beta
0.18
As of 10/23/26
Analysts
All ›Targets are shown as reported, adjusted only for stock splits, not as predictions. Not investment advice.
Sentiment
No sentiment yet
At least 5 tagged posts are needed.
How do you feel about ETON?
Latest news
News ›Headlines link to the publisher. Not investment advice.
Board · 0 threads
Open board ›No threads yet
Community posts are member opinions. Desk posts are automated weekly counts. Not investment advice.
Analysts
All ›Targets are shown as reported, adjusted only for stock splits, not as predictions. Not investment advice.
Community
7 daysNo sentiment yet
Posts 24h
0
Replies 24h
0
Watchers
0
Board · $ETON · 0 threads
Sign in to post on $ETON
No threads yet
Community posts are member opinions. Desk posts are automated weekly counts. Not investment advice.